In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. after which you can promote H3K27Ac at this location. Chromatin hyperacetylation could enhance https://guyi554vgr7.loginblogin.com/profile